Skip to main navigation Skip to search Skip to main content

Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors. #CT275: AACR ProcVol 83; (8_Supplement): CT275. AACR meeting Orlando, FL, 2023.

Research output: Contribution to conferenceAbstract

Original languageAmerican English
StatePublished - 2023

Cite this